This trial is active, not recruiting.

Condition dengue
Treatments placebo, chloroquine
Phase phase 1/phase 2
Sponsor University of Sao Paulo
Collaborator Fundação de Amparo à Pesquisa do Estado de São Paulo
Start date February 2008
End date May 2008
Trial size 132 participants
Trial identifier NCT00849602, BALF-01


The objective of this study was to evaluate the effect of chloroquine in the treatment of patients with dengue.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
(Placebo Comparator)
Placebo bid for three days
(Active Comparator)
Chloroquine bid for three days

Primary Outcomes

Duration of the disease
time frame: one week

Secondary Outcomes

Intensity and days of fever and symptoms
time frame: one week

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patients suspected of having dengue disease - Patients were included in the study if they presented with fever and at least two other symptoms, such as: - headache - pain behind the eyes - muscle and bone or joint pains - nausea - vomiting - rash associated to dengue for less than 72 hours Exclusion Criteria: - Pregnant - Younger than 18-years old - Either cardiac or neurologic disease

Additional Information

Official title The Effect of Chloroquine in the Treatment of Patients With Dengue
Principal investigator Benedito AL Fonseca, PhD
Trial information was received from ClinicalTrials.gov and was last updated in February 2009.
Information provided to ClinicalTrials.gov by University of Sao Paulo.